vs
QuidelOrtho Corp（QDEL）与TRINET GROUP, INC.（TNET）财务数据对比。点击上方公司名可切换其他公司
TRINET GROUP, INC.的季度营收约是QuidelOrtho Corp的1.8倍（$1.2B vs $699.9M），TRINET GROUP, INC.同比增速更快（-2.2% vs -3.7%），TRINET GROUP, INC.自由现金流更多（$43.0M vs $-94.7M），过去两年TRINET GROUP, INC.的营收复合增速更高（-0.6% vs -2.9%）
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
TriNet Group, Inc.是一家面向中小企业的专业雇主组织，总部位于加州都柏林，服务员工规模在3至2500人之间的各类机构。可提供薪资管理、健康福利管理服务，还能为客户提供劳动法规合规、风险降低相关咨询，可作为外包人力资源部门为企业分担人事相关事务。
QDEL vs TNET — 直观对比
营收规模更大
TNET
是对方的1.8倍
$699.9M
营收增速更快
TNET
高出1.5%
-3.7%
自由现金流更多
TNET
多$137.7M
$-94.7M
两年增速更快
TNET
近两年复合增速
-2.9%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $699.9M | $1.2B |
| 净利润 | $-733.0M | — |
| 毛利率 | — | — |
| 营业利润率 | -100.7% | 0.1% |
| 净利率 | -104.7% | — |
| 营收同比 | -3.7% | -2.2% |
| 净利润同比 | -3583.4% | — |
| 每股收益（稀释后） | $-10.78 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QDELTNET
| Q4 25 | — | $1.2B | ||
| Q3 25 | $699.9M | $1.2B | ||
| Q2 25 | $613.9M | $1.2B | ||
| Q1 25 | $692.8M | $1.3B | ||
| Q4 24 | $707.8M | $1.3B | ||
| Q3 24 | $727.1M | $1.2B | ||
| Q2 24 | $637.0M | $1.2B | ||
| Q1 24 | $711.0M | $1.3B |
净利润QDELTNET
| Q4 25 | — | — | ||
| Q3 25 | $-733.0M | $34.0M | ||
| Q2 25 | $-255.4M | $37.0M | ||
| Q1 25 | $-12.7M | $85.0M | ||
| Q4 24 | $-178.4M | — | ||
| Q3 24 | $-19.9M | $45.0M | ||
| Q2 24 | $-147.7M | $60.0M | ||
| Q1 24 | $-1.7B | $91.0M |
营业利润率QDELTNET
| Q4 25 | — | 0.1% | ||
| Q3 25 | -100.7% | 4.1% | ||
| Q2 25 | -29.4% | 4.1% | ||
| Q1 25 | 4.7% | 8.9% | ||
| Q4 24 | -14.2% | -2.9% | ||
| Q3 24 | 2.1% | 4.7% | ||
| Q2 24 | -18.4% | 6.5% | ||
| Q1 24 | -247.3% | 9.7% |
净利率QDELTNET
| Q4 25 | — | — | ||
| Q3 25 | -104.7% | 2.8% | ||
| Q2 25 | -41.6% | 3.0% | ||
| Q1 25 | -1.8% | 6.6% | ||
| Q4 24 | -25.2% | — | ||
| Q3 24 | -2.7% | 3.6% | ||
| Q2 24 | -23.2% | 4.9% | ||
| Q1 24 | -239.9% | 7.2% |
每股收益（稀释后）QDELTNET
| Q4 25 | — | $0.02 | ||
| Q3 25 | $-10.78 | $0.70 | ||
| Q2 25 | $-3.77 | $0.77 | ||
| Q1 25 | $-0.19 | $1.71 | ||
| Q4 24 | $-2.54 | $-0.44 | ||
| Q3 24 | $-0.30 | $0.89 | ||
| Q2 24 | $-2.20 | $1.20 | ||
| Q1 24 | $-25.50 | $1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.1M | $287.0M |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $2.0B | $54.0M |
| 总资产 | $5.7B | $3.8B |
| 负债/权益比越低杠杆越低 | 1.23× | — |
8季度趋势，按日历期对齐
现金及短期投资QDELTNET
| Q4 25 | — | $287.0M | ||
| Q3 25 | $98.1M | $321.0M | ||
| Q2 25 | $151.7M | $407.0M | ||
| Q1 25 | $127.1M | $349.0M | ||
| Q4 24 | $98.3M | $360.0M | ||
| Q3 24 | $143.7M | $301.0M | ||
| Q2 24 | $107.0M | $249.0M | ||
| Q1 24 | $78.5M | $383.0M |
总债务QDELTNET
| Q4 25 | — | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — |
股东权益QDELTNET
| Q4 25 | — | $54.0M | ||
| Q3 25 | $2.0B | $110.0M | ||
| Q2 25 | $2.8B | $107.0M | ||
| Q1 25 | $3.0B | $63.0M | ||
| Q4 24 | $3.0B | $69.0M | ||
| Q3 24 | $3.2B | $129.0M | ||
| Q2 24 | $3.2B | $100.0M | ||
| Q1 24 | $3.3B | $143.0M |
总资产QDELTNET
| Q4 25 | — | $3.8B | ||
| Q3 25 | $5.7B | $3.4B | ||
| Q2 25 | $6.4B | $3.7B | ||
| Q1 25 | $6.5B | $3.8B | ||
| Q4 24 | $6.4B | $4.1B | ||
| Q3 24 | $6.8B | $3.7B | ||
| Q2 24 | $6.7B | $3.7B | ||
| Q1 24 | $6.7B | $4.0B |
负债/权益比QDELTNET
| Q4 25 | — | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-45.5M | $61.0M |
| 自由现金流经营现金流 - 资本支出 | $-94.7M | $43.0M |
| 自由现金流率自由现金流/营收 | -13.5% | 3.4% |
| 资本支出强度资本支出/营收 | 7.0% | 1.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-153.1M | $234.0M |
8季度趋势，按日历期对齐
经营现金流QDELTNET
| Q4 25 | — | $61.0M | ||
| Q3 25 | $-45.5M | $72.0M | ||
| Q2 25 | $-46.8M | $75.0M | ||
| Q1 25 | $65.6M | $95.0M | ||
| Q4 24 | $63.7M | $65.0M | ||
| Q3 24 | $117.9M | $84.0M | ||
| Q2 24 | $-97.9M | $39.0M | ||
| Q1 24 | $-700.0K | $91.0M |
自由现金流QDELTNET
| Q4 25 | — | $43.0M | ||
| Q3 25 | $-94.7M | $55.0M | ||
| Q2 25 | $-84.3M | $57.0M | ||
| Q1 25 | $9.4M | $79.0M | ||
| Q4 24 | $16.5M | $47.0M | ||
| Q3 24 | $71.4M | $59.0M | ||
| Q2 24 | $-133.2M | $22.0M | ||
| Q1 24 | $-66.8M | $73.0M |
自由现金流率QDELTNET
| Q4 25 | — | 3.4% | ||
| Q3 25 | -13.5% | 4.5% | ||
| Q2 25 | -13.7% | 4.6% | ||
| Q1 25 | 1.4% | 6.1% | ||
| Q4 24 | 2.3% | 3.7% | ||
| Q3 24 | 9.8% | 4.8% | ||
| Q2 24 | -20.9% | 1.8% | ||
| Q1 24 | -9.4% | 5.8% |
资本支出强度QDELTNET
| Q4 25 | — | 1.4% | ||
| Q3 25 | 7.0% | 1.4% | ||
| Q2 25 | 6.1% | 1.5% | ||
| Q1 25 | 8.1% | 1.2% | ||
| Q4 24 | 6.7% | 1.4% | ||
| Q3 24 | 6.4% | 2.0% | ||
| Q2 24 | 5.5% | 1.4% | ||
| Q1 24 | 9.3% | 1.4% |
现金转化率QDELTNET
| Q4 25 | — | — | ||
| Q3 25 | — | 2.12× | ||
| Q2 25 | — | 2.03× | ||
| Q1 25 | — | 1.12× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | 0.65× | ||
| Q1 24 | — | 1.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
TNET
| Insurance Services | $1.1B | 85% |
| Professional Services | $169.0M | 14% |
